Investors + Media

Corporate Profile

AveXis, Inc. is a clinical-stage gene therapy company, dedicated to developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Our initial product candidate, AVXS-101, is our proprietary gene therapy product candidate currently in development for the treatment of spinal muscular atrophy, or SMA, Type 1, the leading genetic cause of infant mortality. The U.S. Food and Drug Administration, or FDA, has granted AVXS-101 Orphan Drug Designation for the treatment of all types of SMA and Breakthrough Therapy Designation, as well as Fast Track Designation for the treatment of SMA Type 1. In addition to developing AVXS-101 to treat SMA Type 1, we plan to develop AVXS-101 to treat additional SMA types and develop other novel treatments for rare neurological genetic diseases.

Recent News

More 
03/16/17
AveXis Reports Topline Results from Phase 1 Trial of AVXS-101 in SMA Type 1 and Fourth Quarter and Full Year 2016 Financial and Operating Results
03/09/17
AveXis to Report Topline Phase 1 Trial Results in SMA Type 1 and Fourth Quarter and Full Year 2016 Financial and Operating Results on March 16, 2017
03/02/17
AveXis to Present Results from Phase 1 Trial of AVXS-101 in SMA Type 1 at AAN Annual Meeting

Upcoming Events

More 
There are currently no events scheduled.

E-MAIL ALERTS

Sign up to receive e-mail alerts whenever AveXis, Inc. posts new information to the site. Just enter your e-mail address and click Submit.

IR CONTACT

Jim Goff
Vice President, Investor Relations and Corporate Communications
Phone: (650) 862-4134
E-mail: jgoff@avexis.com


Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources

© AveXis, Inc. All Rights Reserved.